Contributions
Abstract: P660
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS Variants
Introduction: MOG-IgG associated acquired demyelinating syndromes (ADS) involve a spectrum of clinical manifestations that are seen in both adult and pediatric patients. This spectrum of MOG-IgG associated ADS is rare, but incidence estimates are not yet available.
Objectives: to assess the nationwide incidence of MOG-IgG associated ADS in the Netherlands and to describe the clinical and serological characteristics of the patients within the MOG-IgG spectrum.
Methods: all serum samples for MOG-IgG testing for routine diagnostics from February 2014 until December 2017 were sent to the single central reference laboratory in the Netherlands. Serum was tested with a well-validated full-length MOG-IgG cell-based assay. Incidence figures were calculated using population data. Detailed clinical data from patients known in our national ADS centre were available.
Results: in total, 1414 samples of 1277 patients were received and of these, 92 patients (7%) were MOG-IgG seropositive. The mean incidence was 0.16 per 100,000 people, with higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000). In Erasmus MC MOG-IgG positive patients (61/92, 66%), we found an equal gender distribution and a predominance for Caucasians. The most common presenting phenotype is ADEM (56%) in children and ON (44%) in adults. Relapsing disease occurred in 9/34 (26%) children and 11/27 (41%) adults during a median follow-up (FU) of 27.5 months. The median time-to-first-relapse (TTFR) was 5.8 months (IQR 2.5-10.1 months). Three patients were tested MOG-IgG positive >200 months after the initial attack, suggesting an extended TTFR. Longitudinal analysis of MOG-IgG (26/61,43%) showed that 67% of the monophasic patients remain seropositive (median onset-to last-sampling time 21.7 months) and 64% in relapsing patients.
Conclusion: the Dutch nationwide incidence of MOG-IgG seropositivity is low and confirms the suspected rarity of MOG-IgG associated demyelination. Seropositivity can be maintained over years even without clinical activity.
Disclosure: C. Louk de Mol - reports no disclosures
Yu Yi M. Wong - reports no disclosures
E. Daniëlle van Pelt - reports no disclosures
Beatrijs. H.A. Wokke - reports no disclosures
Dorine Siepman - reports no disclosures
Rinze F. Neuteboom - reports no disclosures
Dörte Hamann - reports no disclosures
Rogier Q. Hintzen - Received honoraria for serving on advisory boards for Biogen Idec, Roche, Sanofi. He participated in trials with BiogenIdec, Merck-Serono, Roche, Genzyme and Novartis
Abstract: P660
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS Variants
Introduction: MOG-IgG associated acquired demyelinating syndromes (ADS) involve a spectrum of clinical manifestations that are seen in both adult and pediatric patients. This spectrum of MOG-IgG associated ADS is rare, but incidence estimates are not yet available.
Objectives: to assess the nationwide incidence of MOG-IgG associated ADS in the Netherlands and to describe the clinical and serological characteristics of the patients within the MOG-IgG spectrum.
Methods: all serum samples for MOG-IgG testing for routine diagnostics from February 2014 until December 2017 were sent to the single central reference laboratory in the Netherlands. Serum was tested with a well-validated full-length MOG-IgG cell-based assay. Incidence figures were calculated using population data. Detailed clinical data from patients known in our national ADS centre were available.
Results: in total, 1414 samples of 1277 patients were received and of these, 92 patients (7%) were MOG-IgG seropositive. The mean incidence was 0.16 per 100,000 people, with higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000). In Erasmus MC MOG-IgG positive patients (61/92, 66%), we found an equal gender distribution and a predominance for Caucasians. The most common presenting phenotype is ADEM (56%) in children and ON (44%) in adults. Relapsing disease occurred in 9/34 (26%) children and 11/27 (41%) adults during a median follow-up (FU) of 27.5 months. The median time-to-first-relapse (TTFR) was 5.8 months (IQR 2.5-10.1 months). Three patients were tested MOG-IgG positive >200 months after the initial attack, suggesting an extended TTFR. Longitudinal analysis of MOG-IgG (26/61,43%) showed that 67% of the monophasic patients remain seropositive (median onset-to last-sampling time 21.7 months) and 64% in relapsing patients.
Conclusion: the Dutch nationwide incidence of MOG-IgG seropositivity is low and confirms the suspected rarity of MOG-IgG associated demyelination. Seropositivity can be maintained over years even without clinical activity.
Disclosure: C. Louk de Mol - reports no disclosures
Yu Yi M. Wong - reports no disclosures
E. Daniëlle van Pelt - reports no disclosures
Beatrijs. H.A. Wokke - reports no disclosures
Dorine Siepman - reports no disclosures
Rinze F. Neuteboom - reports no disclosures
Dörte Hamann - reports no disclosures
Rogier Q. Hintzen - Received honoraria for serving on advisory boards for Biogen Idec, Roche, Sanofi. He participated in trials with BiogenIdec, Merck-Serono, Roche, Genzyme and Novartis